Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,478,100
  • Shares Outstanding, K 69,240
  • Annual Sales, $ 771,400 K
  • Annual Income, $ 21,800 K
  • 36-Month Beta 0.24
  • Price/Sales 3.24
  • Price/Cash Flow 20.34
  • Price/Book 2.87

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.06 +8.26%
on 12/19/17
36.44 -1.78%
on 01/12/18
+2.32 (+6.93%)
since 12/15/17
3-Month
27.23 +31.44%
on 11/02/17
36.44 -1.78%
on 01/12/18
-0.31 (-0.86%)
since 10/16/17
52-Week
15.15 +136.24%
on 02/07/17
37.30 -4.05%
on 10/09/17
+19.46 (+119.17%)
since 01/13/17

Most Recent Stories

More News
Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod

Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.

AMED : 57.03 (+4.15%)
MYGN : 35.79 (-0.72%)
BIO : 249.11 (+0.30%)
ISRG : 420.07 (+0.25%)
AstraZeneca's Lynparza Label Now Includes Breast Cancer

AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

AZN : 34.99 (-1.85%)
MRK : 62.07 (+5.81%)
MYGN : 35.79 (-0.72%)
CLVS : 55.41 (-6.10%)
LYNPARZA(R) (olaparib) Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer

--LYNPARZA reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy

AZN : 34.99 (-1.85%)
MRK : 62.07 (+5.81%)
MYGN : 35.79 (-0.72%)
U.S. FDA Approves LYNPARZA(R) (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer

--LYNPARZA Reduced Risk of Disease Progression or Death by 42 Percent Compared to Standard of Care Chemotherapy

MYGN : 35.79 (-0.72%)
MRK : 62.07 (+5.81%)
Myriad Receives FDA Approval of BRACAnalysis CDx(R) as Companion Diagnostic for Lynparza(TM) (olaparib) In Patients with Metastatic Breast Cancer

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) approved BRACAnalysis CDx(R) for use as...

MYGN : 35.79 (-0.72%)
Wired News - Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca

Stock Monitor: AstraZeneca Post Earnings Reporting

AZN : 34.99 (-1.85%)
MYGN : 35.79 (-0.72%)
Myriad Genetics Rises 1.27% on Heavy Volume: Watch For Potential Pullback

Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $34.53 to a high of $35.10. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of...

MYGN : 35.79 (-0.72%)
Watch for Myriad Genetics to Potentially Pullback After Gaining 1.27% Yesterday

Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $34.53 to a high of $35.10. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of...

MYGN : 35.79 (-0.72%)
Myriad Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the JP Morgan Annual...

JPM : 112.27 (-0.36%)
MYGN : 35.79 (-0.72%)
Teleflex (TFX), HealthTrust Rebond on Respiratory Products

Teleflex's (TFX) exclusive contracts with HealthTrust provide benefits to the latter with an opportunity to consolidate its members' respiratory purchases with the same supplier.

PETS : 51.78 (-2.19%)
TFX : 262.93 (-0.09%)
MYGN : 35.79 (-0.72%)
ALGN : 263.88 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering...

See More

Key Turning Points

2nd Resistance Point 36.50
1st Resistance Point 36.14
Last Price 35.79
1st Support Level 35.60
2nd Support Level 35.42

See More

52-Week High 37.30
Last Price 35.79
Fibonacci 61.8% 28.84
Fibonacci 50% 26.22
Fibonacci 38.2% 23.61
52-Week Low 15.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.